Technical Analysis for APRE - Aprea Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | -2.90% | |
| Wide Bands | Range Expansion | -2.90% | |
| Oversold Stochastic | Weakness | -2.90% | |
| 50 DMA Resistance | Bearish | -3.22% | |
| Lower Bollinger Band Walk | Weakness | -3.22% | |
| Wide Bands | Range Expansion | -3.22% | |
| Oversold Stochastic | Weakness | -3.22% | |
| 50 DMA Resistance | Bearish | -1.92% | |
| Lower Bollinger Band Walk | Weakness | -1.92% | |
| Wide Bands | Range Expansion | -1.92% |
| Alert | Time |
|---|---|
| Down 3% | about 2 hours ago |
| Down 2 % | about 2 hours ago |
| Down 1% | about 2 hours ago |
| Fell Below Previous Day's Low | 1 day ago |
| Down 2 % | 1 day ago |
Get this analysis on your stocks daily!
- Earnings date: 11/07/2024
Aprea Therapeutics, Inc. Description
Aprea Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The company's lead drug candidate APR-246, a small molecule p53 reactivator, is in clinical development for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as additional hematologic and solid tumor malignancies. It has commenced a Phase 3 clinical trial in p53 mutant MDS and completed enrollment in a Phase 1b/2 clinical trial in p53 mutant MDS and AML with APR-246 and azacitidine; and additional Phase 1/2 trials of APR-246 in MDS and AML in combination with approved anti-cancer therapies, as well as developing next generation p53 reactivators. The company was founded in 2003 and is based in Boston, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Tumor Acute Myeloid Leukemia Cancer Therapies Myelodysplastic Syndrome Syndromes P53 Tumor Suppressor Genes Anti Cancer Therapies Tumor Suppressor
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 8.8465 |
| 52 Week Low | 2.1501 |
| Average Volume | 26,991 |
| 200-Day Moving Average | 4.59 |
| 50-Day Moving Average | 3.33 |
| 20-Day Moving Average | 3.68 |
| 10-Day Moving Average | 3.34 |
| Average True Range | 0.36 |
| RSI (14) | 36.31 |
| ADX | 27.08 |
| +DI | 11.30 |
| -DI | 22.98 |
| Chandelier Exit (Long, 3 ATRs) | 3.35 |
| Chandelier Exit (Short, 3 ATRs) | 3.94 |
| Upper Bollinger Bands | 4.51 |
| Lower Bollinger Band | 2.86 |
| Percent B (%b) | 0.09 |
| BandWidth | 44.80 |
| MACD Line | -0.12 |
| MACD Signal Line | 0.00 |
| MACD Histogram | -0.1243 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.39 | ||||
| Resistance 3 (R3) | 3.39 | 3.25 | 3.33 | ||
| Resistance 2 (R2) | 3.25 | 3.16 | 3.26 | 3.31 | |
| Resistance 1 (R1) | 3.13 | 3.10 | 3.19 | 3.14 | 3.29 |
| Pivot Point | 3.00 | 3.00 | 3.03 | 3.00 | 3.00 |
| Support 1 (S1) | 2.88 | 2.90 | 2.94 | 2.88 | 2.73 |
| Support 2 (S2) | 2.74 | 2.84 | 2.75 | 2.71 | |
| Support 3 (S3) | 2.62 | 2.74 | 2.69 | ||
| Support 4 (S4) | 2.63 |
